BCAX - Bicara Therapeutics Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.60
DETAILS
HIGH:
$42.00
LOW:
$18.00
MEDIAN:
$28.00
CONSENSUS:
$28.60
UPSIDE:
31.92%
About Bicara Therapeutics Inc. Common Stock (https://www.bicara.com)
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Claire Mazumdar Clemon | Chief Executive Officer & Director | 1990 | $927,688 USD |
| Ivan Hyep | CFO & Treasurer | 1985 | $915,375 USD |
| Ryan Cohlhepp | President, Chief Operating Officer & Director | 1977 | $858,400 USD |
| David Raben | Chief Medical Officer | 1964 | $709,164 USD |
| Angela Windt | Vice President & Head of Regulatory Affairs | – | – |
| Gary Bostanxhi | Vice President of Finance & Controller | – | – |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance | – | – |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | – | – |
| Jenna Cohen | Chief Corporate Affairs Officer | – | – |
| Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | 1972 | – |
| Pauline Dufresne | Chief People Officer | – | – |
| Rachel Salazar | SVP of R&D Strategy and Operations | – | – |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | – | – |
| Tanya Green | Chief Development Officer | – | – |